Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7010262 | 0.87 | KMT2A (0.59) | HPGDMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL13491694 | 0.87 | MAPK14 (0.54) | HPGDSMN1; SMN2POLBCYP3A4MAPT | |
| SCHEMBL13491697 | 0.87 | MAPK8 (0.54) | HPGDSMN1; SMN2LMNAPOLBCYP3A4 | |
| SCHEMBL2357356 | 0.85 | POLB (0.54) | RAB9AMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL13491699 | 0.85 | CYP3A4 (0.53) | KMT2APOLBCYP3A4MAPTHDAC3 | |
| SCHEMBL7017456 | 0.85 | POLB (0.64) | RAB9AEGLN1HPGDALDH1A1POLB | |
| SCHEMBL13491655 | 0.84 | KMT2A (0.55) | EGLN1KMT2ASMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL1681445 | 0.84 | LMNA (0.53) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL7014947 | 0.83 | EGLN1 (0.64) | RAB9AEGLN1HPGDMEN1KMT2A | |
| SCHEMBL7014019 | 0.83 | TSHR (0.59) | HPGDMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605614-B2 | Anti-hepatitis or anti-herpes | BIOCHEM PHARMA INC. (CA) | 2003-08-12 | — | — | US | claimed |
| JP-2002537396-A | — | — | 2002-11-05 | — | — | JP | claimed |
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | BIOCHEM PHARMA INC. | 2002-07-25 | — | — | US | claimed |
| US-6340690-B1 | INHIBITING HEPATITIS OR HERPES VIRAL INFECTIONS | BIO-CHEM PHARMA INC. (CA) | 2002-01-22 | — | — | US | claimed |
| EP-1155017-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | Shire Biochem Inc. (CA) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050424-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | BIOCHEM PHARMA INC. (CA) | 2000-08-31 | — | — | WO | claimed |
| US-6605614-B2 | Anti-hepatitis or anti-herpes | BIOCHEM PHARMA INC. (CA) | 2003-08-12 | — | — | US | disclosed |
| EP-1155017-B1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | SHIRE BIOCHEM INC (CA) | 2003-01-15 | — | — | EP | disclosed |
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | BIOCHEM PHARMA INC. | 2002-07-25 | — | — | US | disclosed |
| US-6340690-B1 | INHIBITING HEPATITIS OR HERPES VIRAL INFECTIONS | BIO-CHEM PHARMA INC. (CA) | 2002-01-22 | — | — | US | disclosed |
| EP-1155017-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | Shire Biochem Inc. (CA) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050424-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | BIOCHEM PHARMA INC. (CA) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | HAVCR2, MAVS, NTPCR | RAB9A 1107/4885EGLN1 3629/4885HPGD 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.